Yang W, Lu J, Weng J, Jia W, Ji L, Ji Q, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.

Article  CAS  PubMed  Google Scholar 

Tseng VL, Greenberg PB, Scott IU, Anderson KL. Compliance with the American Academy of Ophthalmology Preferred Practice Pattern for Diabetic Retinopathy in a resident ophthalmology clinic. Retina. 2010;30(5):787–94.

Article  PubMed  Google Scholar 

Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013;131(8):1033–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88(3):279–91.

Article  CAS  Google Scholar 

Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2009;148(6):883–9.

Article  CAS  PubMed  Google Scholar 

Ferenchak K, Duval R, Cohen JA, MacCumber MW. Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy. Retina. 2014;34(6):1177–81.

Article  CAS  PubMed  Google Scholar 

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.

Article  CAS  PubMed  Google Scholar 

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–9.

Article  PubMed  Google Scholar 

Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2009;26(1):204–10.

Article  CAS  PubMed  Google Scholar 

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology. 2020;127(2):198–210.

Article  PubMed  Google Scholar 

Jung BJ, Kim JY, Lee JH, Baek J, Lee K, Lee WK. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep. 2019;9(1):2055.

Article  PubMed  PubMed Central  Google Scholar 

Ren X, Bu S, Zhang X, Jiang Y, Tan L, Zhang H, et al. Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy. Eye (Lond). 2019;33(7):1177–83.

Article  CAS  Google Scholar 

Yang X, Xu J, Wang R, Mei Y, Lei H, Liu J, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy. J Ophthalmol. 2016;2016:2473234.

Article  PubMed  PubMed Central  Google Scholar 

Cui J, Chen H, Lu H, Dong F, Wei D, Jiao Y, et al. Efficacy and safety of intravitreal conbercept, ranibizumab, and triamcinolone on 23-gauge vitrectomy for patients with proliferative diabetic retinopathy. J Ophthalmol. 2018;2018:4927259.

Article  PubMed  PubMed Central  Google Scholar 

Rosenfeld PJ, Durbin MK, Roisman L, Zheng F, Miller A, Robbins G, et al. ZEISS Angioplex™ spectral domain optical coherence tomography angiography: technical aspects. Dev Ophthalmol. 2016;56:18–29.

Article  PubMed  Google Scholar 

Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118(11):2218–26.

Article  PubMed  Google Scholar 

Suzuki Y, Suzuki K, Yokoi Y, Miyagawa Y, Metoki T, Nakazawa M. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Retina. 2014;34(1):165–71.

Article  CAS  PubMed  Google Scholar 

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet. 2010;376(9735):124–36.

Google Scholar 

Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, et al. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol. 2010;150(2):223-9.e1.

Article  CAS  PubMed  Google Scholar 

Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond). 2009;23(1):108–11.

Article  CAS  Google Scholar 

Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29(6):10–4.

Article  CAS  PubMed  Google Scholar 

De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):1–9.

Article  PubMed  PubMed Central  Google Scholar 

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22.

Article  Google Scholar 

Yu DC, Lee JS, Yoo JY, Shin H, Deng H, Wei Y, et al. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol Ther. 2012;20(5):938–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Dev Ther. 2015;9:2311–20.

CAS  Google Scholar 

Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98(6):813–25.

Article  PubMed  Google Scholar 

Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197:156–67.

Article  CAS  PubMed  Google Scholar 

Yang KB, Zhang H, Li SJ, Cao JJ, Cheng LN, Lin YX, et al. Conbercept and ranibizumab pretreatments in vitrectomy with silicone oil infusion for severe diabetic retinopathy. J Ocul Pharmacol Ther. 2019;35(3):161–7.

Article  PubMed  Google Scholar 

Yin N, Zhao S, Zhu HN. Efficacy comparison of conbercept and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Guo Ji Yan Ke Za Zhi. 2017;17(7):1300–2.

Google Scholar 

Lu Q, Lu L, Chen B, Chen W, Lu P. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy. Can J Ophthalmol. 2019;54(3):291–6.

Article  PubMed  Google Scholar 

Storti F, Pulley J, Kuner P, Abt M, Luhmann UFO. Circulating biomarkers of inflammation and endothelial activation in diabetic retinopathy. Transl Vis Sci Technol. 2021;10(12):8.

Article  PubMed  PubMed Central  Google Scholar 

Xia JP, Liu SQ, Wang S. Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress. Life Sci. 2021;265:118795.

Article  CAS  PubMed  Google Scholar 

Chen Y, Hua R. Therapeutic efficacy of conbercept for inflammatory choroidal neovascularization. J Ocul Pharmacol Ther. 2018;34(3):235–6.

Article  CAS  PubMed  Google Scholar 

Chen R, Wu B. Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. Ann Transl Med. 2020;8(15):939.

Article  PubMed  PubMed Central  Google Scholar 

Cui Z, Zhou W, Chang Q, Zhang T, Wang H, Meng X, et al. Cost-effectiveness of conbercept vs. ranibizumab for age-related macular degeneration, diabetic macular edema, and pathological myopia: population-based cohort study and Markov model. Front Med (Lausanne). 2021;8:750132.

Article  Google Scholar